Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Egbert F Smit

Showing results (21-30 of 367) with videos related to

Pageof 37
Sort By:
PET Clinics|May 10, 2016
Evaluation of Cost-effectiveness of FDG-PET in Non-Small Cell Lung CancerOtto S Hoekstra, Harm van Tinteren, Egbert F Smit
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2005
FDG-PET in addition to conventional work-up in non-small-cell lung cancerHarm van Tinteren, Egbert F Smit, Otto S Hoekstra
Cancer Treatment Reviews|March 19, 2021
Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studiesYi-Long Wu, Egbert F Smit, Todd M Bauer
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 2, 2010
Osteoblastic bone lesions developing during treatment with erlotinib indicate major response in patients with non-small cell lung cancer: a brief reportJoline S W Lind, Pieter E Postmus, Egbert F Smit
Expert Opinion on Investigational Drugs|October 8, 2011
Low molecular weight heparins in the treatment of lung cancerWouter W Mellema, Egbert F Smit, Anne-Marie C Dingemans
The Lancet. Oncology|August 8, 2015
Surgery versus SABR for resectable non-small-cell lung cancer - Authors' replyJoe Y Chang, Suresh Senan, Egbert F Smit, et al.
Pharmacoeconomics|November 10, 2005
Economic evaluation of three two-drug chemotherapy regimens in advanced non-small-cell lung cancerNiels Neymark, Pilar Lianes, Egbert F Smit, et al.
Expert Opinion on Pharmacotherapy|March 24, 2015
Pharmacotherapy for treatment of lung cancer in the elderlyBianca A M H van Veggel, Bonne Biesma, Egbert F Smit
The Lancet. Oncology|February 13, 2016
Stereotactic radiotherapy or surgery for early-stage non-small-cell lung cancer - Authors' replyJoe Y Chang, Suresh Senan, Egbert F Smit, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 26, 2010
Side-effects of long-term administration of erlotinib in patients with non-small cell lung cancerAnnemarie Becker, Atie van Wijk, Egbert F Smit, et al.
Pageof 37

Showing results (21-30 of 367) with videos related to

Sort By:
Pageof 37
PET Clinics|May 10, 2016
Evaluation of Cost-effectiveness of FDG-PET in Non-Small Cell Lung CancerOtto S Hoekstra, Harm van Tinteren, Egbert F Smit
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2005
FDG-PET in addition to conventional work-up in non-small-cell lung cancerHarm van Tinteren, Egbert F Smit, Otto S Hoekstra
Cancer Treatment Reviews|March 19, 2021
Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studiesYi-Long Wu, Egbert F Smit, Todd M Bauer
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 2, 2010
Osteoblastic bone lesions developing during treatment with erlotinib indicate major response in patients with non-small cell lung cancer: a brief reportJoline S W Lind, Pieter E Postmus, Egbert F Smit
Expert Opinion on Investigational Drugs|October 8, 2011
Low molecular weight heparins in the treatment of lung cancerWouter W Mellema, Egbert F Smit, Anne-Marie C Dingemans
The Lancet. Oncology|August 8, 2015
Surgery versus SABR for resectable non-small-cell lung cancer - Authors' replyJoe Y Chang, Suresh Senan, Egbert F Smit, et al.
Pharmacoeconomics|November 10, 2005
Economic evaluation of three two-drug chemotherapy regimens in advanced non-small-cell lung cancerNiels Neymark, Pilar Lianes, Egbert F Smit, et al.
Expert Opinion on Pharmacotherapy|March 24, 2015
Pharmacotherapy for treatment of lung cancer in the elderlyBianca A M H van Veggel, Bonne Biesma, Egbert F Smit
The Lancet. Oncology|February 13, 2016
Stereotactic radiotherapy or surgery for early-stage non-small-cell lung cancer - Authors' replyJoe Y Chang, Suresh Senan, Egbert F Smit, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 26, 2010
Side-effects of long-term administration of erlotinib in patients with non-small cell lung cancerAnnemarie Becker, Atie van Wijk, Egbert F Smit, et al.
Pageof 37